Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Dengue vaccine under the microscope: will it keep kids out of the hospital?

NCT ID NCT06843226

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether the dengue vaccine (TDV) helps prevent hospital stays due to dengue in children and teens in Thailand, Indonesia, and Malaysia. Researchers will follow 70,000 participants for 3 years, comparing those who got the vaccine with those who did not. The goal is to gather real-world data on how well the vaccine works, especially against less common dengue types.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could confirm that the dengue vaccine effectively prevents severe dengue leading to hospitalization in children and teens.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also limited to specific countries and may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pediatric and/or adolescent residents in the study area who are age-eligible for vaccination with TDV as part of a pilot public vaccination program (children 7-10 years in Thailand, 6-10 years in Indonesia, and 7-12 years in Malaysia).

Ages

6 to 12 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Cohort: To be eligible for inclusion in the study cohort, participants must meet the following inclusion criteria: 1. The participant is a child or adolescent eligible to be vaccinated with TDV as part of a vaccination program planned in the study area. 2. The participant's family do not intend to migrate away from the cohort hospital catchment area within 3 years of his/her enrollment into the study cohort. 3. The participant's parent(s) or legally acceptable representative (LAR) signs and dates a written informed consent form (ICF), and any required privacy authorization where applicable, prior to the initiation of any study procedures, after the nature of the study has been explained according to local regulatory requirements. 4. The participant signs and dates an age-appropriate assent form prior to the initiation of any study procedures, after the nature of the study has been explained according to local regulatory requirements. 5. The participant's parent(s) or LAR agrees that a baseline blood sample may be taken from the participant. Cases: To be eligible for inclusion as a case, participants must meet the following inclusion criteria: 1. The participant is part of the cohort. 2. The participant is hospitalized and clinically diagnosed with dengue. 3. The participant has a blood sample available that was taken preferably within 5 days of fever onset and/or onset of symptoms compatible with dengue. 4. The participant tested positive for dengue by RT-PCR. Controls: To be eligible for inclusion as a matched control, participants must meet the following inclusion criteria: 1. The participant is part of the cohort. 2. The participant had not been hospitalized with VCD at any point between enrollment in the cohort and the index date (that is, when his/her matched case was hospitalized with CDD). 3. The participant is a resident in the same neighbourhood as the matched case. 4. The participant's date of birth is in the same calendar year as the matched case. Exclusion Criteria Cases: To be eligible for inclusion as a case participants must not meet any of the following criteria: 1. The participant has been vaccinated with TDV, a tetravalent, live attenuated, chimeric dengue vaccine in a yellow fever 17D backbone (CYD-TDV), or an investigational dengue vaccine prior to cohort enrollment. 2. Contraindications as per the locally approved label/product information leaflet. Controls: To be eligible for inclusion as a control participants must not meet any of the following criteria: 1. The participant has been vaccinated with TDV, CYD-TDV, or an investigational dengue vaccine prior to cohort enrollment. 2. Contraindications as per the locally approved label/product information leaflet. 3. The participant could not be contacted at the time of being selected as a control.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dengue fever are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    4 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Fakultas Kedokteran Lambung Mangkurat

    RECRUITING

    Banjarmasin, South Kalimantan, 70122, Indonesia

  • Fakultas Kedokteran Universitas Indonesia

    RECRUITING

    Jakarta Pusat, 10430, Indonesia

  • Fakultas Kedokteran Universitas Sriwijaya

    RECRUITING

    Palembang, South Sumatra, 30662, Indonesia

  • Nakhon Phanom Hospital

    ACTIVE_NOT_RECRUITING

    Nakhon Phanom, 48000, Thailand

  • Pattaya Patamakhun Hospital

    ACTIVE_NOT_RECRUITING

    Chon Buri, 20150, Thailand

  • Phra Nakhon Si Ayutthaya Hospital

    ACTIVE_NOT_RECRUITING

    Phra Nakhon Si Ayutthaya, 13000, Thailand

  • Universiti Malaya Medical Centre

    NOT_YET_RECRUITING

    Kuala Lumpur, 59100, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.